Australia markets closed

Smith & Nephew plc (SNN)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
25.45-0.89 (-3.38%)
As of 02:39PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close26.34
Open25.65
Bid25.51 x 3100
Ask25.51 x 800
Day's range25.40 - 25.83
52-week range21.53 - 33.09
Volume1,889,610
Avg. volume940,001
Market cap11.126B
Beta (5Y monthly)0.51
PE ratio (TTM)42.42
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield0.75 (2.85%)
Ex-dividend date01 Apr 2024
1y target estN/A
  • GlobeNewswire

    Smith+Nephew teams up with UFC to be first-ever Preferred Sports Medicine Technology Partner

    Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has been named the Preferred Sports Medicine Technology Partner of UFC – the world’s premier mixed martial arts organization and one of the foremost global brands in all of sports. Under the terms of the multi-year partnership, Smith+Nephew will activate its brand through UFC’s immense global presence to promote the repair, regeneration and recovery of Sports Medicine injuries through advanced technologies

  • GlobeNewswire

    Smith+Nephew and U.S. Army Institute of Surgical Research to engage in Master Cooperative Research and Development Agreement

    Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announced they have entered into a Master Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR). This marks the first time that the USAISR has entered into a master agreement of this nature with an industry-leading medical technology company. The Master CRADA represents an enterprise-wide opportunity for Smith+Nephew across all business units - Advanced Wound

  • GlobeNewswire

    Smith+Nephew announces commercial launch of its AETOS™ Shoulder System for anatomic and reverse shoulder replacement at AAOS 2024 Annual Meeting

    Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces full commercial availability of its AETOS Shoulder System in the US, along with 510(k) clearance for its use with ATLASPLAN◊ 3D Planning Software and Patient Specific Instrumentation for total shoulder arthroplasty. Total shoulder arthroplasty is one of the fastest growing segments in Orthopaedics with an estimated 250,000 procedures in the US by 2025.1 Developed to restore patients’ range-of-motion2-5 and he